Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6179935 | 0.80 | CA12 (0.51) | ALDH1A1 | |
| SCHEMBL6406957 | 0.79 | CA12 (0.61) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL15317923 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL27543987 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL8936163 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1KMT2ATDP1 | |
| SCHEMBL10679748 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL3803222 | 0.77 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| Guanidine SCHEMBL27358697 | 0.77 | ALDH1A1 (0.57) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL7236939 | 0.77 | MAPT (0.46) | — | |
| SCHEMBL9514032 | 0.75 | ALDH1A1 (0.41) | ALDH1A1MAPK1L3MBTL1SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9908849-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA | 2017-06-15 | — | — | US | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-9421177-B2 | Imidamide sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-23 | — | — | US | disclosed |
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-05-05 | — | — | US | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2009146112-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-1395551-B1 | HYDROXY ALKYL AMINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND THEIR USE FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND SIMILAR DISEASES | ELAN PHARM INC (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20070299263-A1 | Hydroxy Alkyl Amines | Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company | 2007-12-27 | — | — | US | disclosed |
| EP-1015454-A1 | METHOD OF INHIBITING SERINE PROTEASE ENZYMES | GLAXO GROUP LIMITED (GB) | 2000-07-05 | — | — | EP | disclosed |
| US-6057457-A | ENZYME INHIBITORS FOR PROTEASE OR ENZYMES OF HYDROLYSIS | GLAXO WELLCOME INC. (US) | 2000-05-02 | — | — | US | disclosed |
| US-5994344-A | BRONCHITIS THERAPY | GLAXO WELLCOME INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5952462-A | Transition state analogs | IGEN INTERNATIONAL INC. (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1999012932-A1 | METHOD OF INHIBITING SERINE PROTEASE ENZYMES | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
| WO-1999012931-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
| EP-0891362-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1999-01-20 | — | — | EP | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1997036903-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1997-10-09 | — | — | WO | disclosed |
| EP-0659737-A2 | Catecholamine surrogates useful as B3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | SPHK2, SPHK1, S1PR2 | ALDH1A1 4650/4885MAPK1 607/4885L3MBTL1 3046/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | ALDH1A1 2958/4885MAPK1 3876/4885L3MBTL1 1042/4885 |
| US-20070299263-A1 | Hydroxy Alkyl Amines | MAOA, PSEN2, PSEN1 | ALDH1A1 597/4885MAPK1 3664/4885L3MBTL1 4541/4885 |
| US-20120214858-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | ALDH1A1 4570/4885MAPK1 361/4885L3MBTL1 2676/4885 |
| US-20170166525-A1 | IMIDAMIDE SPHINGOSINE KINASE INHIBITORS | SPHK2, SPHK1, S1PR2 | ALDH1A1 4570/4885MAPK1 361/4885L3MBTL1 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.